Skip to main content

Non-pharmacological augmentation of trauma-focused psychotherapy for PTSD: a systematic review and meta-analysis

In brief

Non-drug add-ons did not improve PTSD therapy outcomes across 39 trials

A meta-analysis of 39 trials involving 2,853 people found no significant overall improvement in PTSD symptoms, treatment response or dropout when non-drug strategies were added to trauma-focused therapy. Sleep-focused strategies showed an add-on benefit, but it remains unclear which patients benefit and whether that effect holds up in further studies.

Journal
European journal of psychotraumatology (Q1)
Published
19 November 2026
Study design
Systematic review / meta-analysis of RCTs
Evidence level
Level 1, High (CEBM 1a)
Authors
Till Langhammer, Lisa Mewes, Jonathan Torbecke, Ricarda Evens, Ulrike Lueken, Johannes Caspar Fendel
PMID
43053690
DOI
10.1080/20008066.2026.2745500

Why clinicians should know about it

  • Picked for Psychiatry and Mental Health (top studies of the week, 22 November 2026): Meta-analysis assesses augmentation of first-line PTSD psychotherapy

Abstract

BACKGROUND: Trauma-focused psychotherapies (TFPs) effectively treat post-traumatic stress disorder (PTSD), yet patients show variable response or discontinue treatment. Numerous augmentation strategies have been developed to address these barriers, but the field lacks a framework that extends beyond mechanistic categories as well as a meta-analytic synthesis of their effects. OBJECTIVE: To develop a classification framework for non-pharmacological augmentation strategies of first-line TFP for PTSD and to meta-analytically evaluate whether these strategies improve treatment outcomes. METHOD: We conducted a systematic review and meta-analysis of randomised controlled trials (RCTs) comparing TFP augmented with a non-pharmacological intervention versus TFP alone or an active control (i.e. sham intervention or dose increase). Eight databases were searched to July 2026. Augmentation strategies were qualitatively categorised. Primary outcomes were PTSD symptom severity and response rate; dropout was a secondary outcome. RESULTS: Fifty RCTs met inclusion criteria. Their augmentations were categorised within a three-level framework comprising targets, mechanisms, and implementation forms. Of these, 39 trials (40 comparisons; N = 2,853) were meta-analysed and showed no significant overall effects (symptom severity: g = -0.10, p = .062; response: RR = 1.04, p = .111; dropout: RR = 0.94, p = .489). One subgroup targeting sleep disturbance showed an add-on effect. CONCLUSIONS: The present findings suggest that augmenting TFP with non-pharmacological interventions does not necessarily lead to incremental efficacy at the overall level, even though small benefits were observed for sleep-focused strategies. Our three-level framework provides a structured approach for conceptualising this heterogeneous field. The absence of a robust overall effect should not be mistaken for evidence that augmentation cannot be effective.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.